Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 CAR-T in Advanced B-Cell Malignancies
NCT04700319Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Apr 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD20 CAR-T cell infusion in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Overall Response Rate at 3 months. Status: unknown.
02
Drugs
CD19/CD20 CAR-T cell infusion
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04700319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700319.